Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy

Patients with severely impaired antibody responses represent a group at-risk in the SARS-CoV-2 pandemic due to the lack of Spike-specific neutralizing antibodies. The main objective of this paper was to assess, by a longitudinal prospective study, COVID-19 infection and mortality rates, and disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Milito, Cinzia, Cinetto, Francesco, Palladino, Andrea, Garzi, Giulia, Punziano, Alessandra, Lagnese, Gianluca, Scarpa, Riccardo, Rattazzi, Marcello, Pesce, Anna Maria, Pulvirenti, Federica, Di Napoli, Giulia, Spadaro, Giuseppe, Carsetti, Rita, Quinti, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138935/
https://www.ncbi.nlm.nih.gov/pubmed/35625763
http://dx.doi.org/10.3390/biomedicines10051026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138935/
https://www.ncbi.nlm.nih.gov/pubmed/35625763
http://dx.doi.org/10.3390/biomedicines10051026

Ejemplares similares